Trading of Cartesian Therapeutics was halted at 09:35 AM EST due to "LULD Pause". NASDAQ:RNAC Cartesian Therapeutics (RNAC) Stock Price, News & Analysis $6.85 +0.99 (+16.89%) Closing price 04:00 PM EasternExtended Trading$6.84 -0.01 (-0.16%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cartesian Therapeutics Stock (NASDAQ:RNAC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cartesian Therapeutics alerts:Sign Up Key Stats Today's Range$6.59▼$9.3350-Day Range$5.84▼$8.7052-Week Range$5.60▼$15.57Volume3.49 million shsAverage Volume208,950 shsMarket Capitalization$201.25 millionP/E RatioN/ADividend YieldN/APrice Target$32.60Consensus RatingModerate Buy Company Overview Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions. At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations. By combining nucleoside‐modified mRNA with bespoke LNP carriers, the company seeks to enhance cellular uptake and reduce immunogenicity, positioning its pipeline candidates for both systemic and localized therapeutic interventions. Cartesian’s preclinical programs include immuno-modulatory candidates intended to boost anti-tumor immunity, as well as mRNA constructs designed to reestablish immune tolerance in autoimmune disease models. The firm has also entered strategic collaborations with academic institutions and contract research organizations to support IND-enabling studies and expand its translational research capabilities. Founded as a spin-out from leading academic research laboratories, Cartesian Therapeutics completed its initial public offering in 2021. Headquartered in New Jersey, the company engages with a broad network of scientific and clinical partners across North America and Europe. Cartesian’s leadership team includes experienced executives drawn from both biotech start-ups and larger pharmaceutical organizations, underscoring its commitment to advancing mRNA science from bench to bedside. As Cartesian progresses toward clinical milestones, it aims to establish itself as a key innovator in the rapidly evolving field of RNA therapeutics.AI Generated. May Contain Errors. Read More Cartesian Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreRNAC MarketRank™: Cartesian Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 681st out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingCartesian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCartesian Therapeutics has a consensus price target of $32.60, representing about 371.9% upside from its current price of $6.91.Amount of Analyst CoverageCartesian Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cartesian Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cartesian Therapeutics are expected to grow in the coming year, from ($4.09) to ($3.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cartesian Therapeutics is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cartesian Therapeutics is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cartesian Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.01% of the float of Cartesian Therapeutics has been sold short.Short Interest Ratio / Days to CoverCartesian Therapeutics has a short interest ratio ("days to cover") of 11.87, which indicates bearish sentiment.Change versus previous monthShort interest in Cartesian Therapeutics has recently increased by 2.17%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCartesian Therapeutics does not currently pay a dividend.Dividend GrowthCartesian Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 5 news articles for Cartesian Therapeutics this week, compared to 2 articles on an average week.Search Interest2 people have searched for RNAC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cartesian Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cartesian Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders37.20% of the stock of Cartesian Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.95% of the stock of Cartesian Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cartesian Therapeutics' insider trading history. Receive RNAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cartesian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNAC Stock News HeadlinesCartesian climbs on licensing deal with WestGene for CAR-T therapies4 hours ago | seekingalpha.comCartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune DiseasesJune 9 at 7:00 AM | globenewswire.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.June 9 at 1:00 AM | Behind the Markets (Ad)Cartesian Therapeutics (RNAC) Gets a Buy from WedbushMay 29, 2026 | theglobeandmail.comCartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027May 26, 2026 | globenewswire.comWe're Keeping An Eye On Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn RateMay 17, 2026 | finance.yahoo.comCartesian Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor ConferenceMay 12, 2026 | quiverquant.comQCartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMay 12, 2026 | globenewswire.comSee More Headlines RNAC Stock Analysis - Frequently Asked Questions How have RNAC shares performed this year? Cartesian Therapeutics' stock was trading at $7.21 at the beginning of the year. Since then, RNAC shares have decreased by 4.2% and is now trading at $6.9080. How were Cartesian Therapeutics' earnings last quarter? Cartesian Therapeutics, Inc. (NASDAQ:RNAC) announced its earnings results on Thursday, April, 30th. The company reported ($1.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by $0.62. The firm earned $0.08 million during the quarter, compared to analyst estimates of $0.22 million. When did Cartesian Therapeutics' stock split? Cartesian Therapeutics's stock reverse split on the morning of Friday, April 5th 2024.The 1-30 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Cartesian Therapeutics IPO? Cartesian Therapeutics (RNAC) raised $75 million in an IPO on Tuesday, June 21st 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Who are Cartesian Therapeutics' major shareholders? Top institutional investors of Cartesian Therapeutics include Renaissance Technologies LLC (0.23%), Public Employees Retirement System of Ohio (0.04%) and Sei Investments Co. (0.04%). Insiders that own company stock include Timothy A Springer, Blaine Davis, Metin Kurtoglu and Milos Miljkovic. View institutional ownership trends. How do I buy shares of Cartesian Therapeutics? Shares of RNAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cartesian Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cartesian Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings4/30/2026Today6/09/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 RNAC's financial health is in the Red zone, according to TradeSmith. RNAC has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNAC Previous SymbolNASDAQ:RNAC CIK1453687 Webselectabio.com Phone617-923-1400Fax617-924-3454Employees64Year Founded2016Price Target and Rating Average Price Target for Cartesian Therapeutics$32.60 High Price Target$44.00 Low Price Target$16.00 Potential Upside/Downside+376.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($5.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$130.30 million Net Margins-8,550.65% Pretax Margin-9,068.56% Return on EquityN/A Return on Assets-28.25% Debt Debt-to-Equity RatioN/A Current Ratio7.65 Quick Ratio7.65 Sales & Book Value Annual Sales$2.80 million Price / Sales71.83 Cash FlowN/A Price / Cash FlowN/A Book Value($4.85) per share Price / Book-1.41Miscellaneous Outstanding Shares29,380,000Free Float18,452,000Market Cap$201.14 million OptionableOptionable Beta0.66 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:RNAC) was last updated on 6/9/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNAC Stock Alerts